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Abstract
The expression of adiponectin receptors AdipoR1 and AdipoR2 has been reported in the human ovary and ovarian cancer tissues.
Moreover, adiponectin has been reported to act as an anti-tumor factor by inhibiting cancer cell proliferation. Thus, we investigate
whether adiponectin and its receptors influence ovarian cancer development. In the present study, we found that adiponectin was
not expressed in the granulosa cell line (COV434), and epithelial ovarian cancer cell lines (OVCAR-3, SKOV-3, and Caov-3).
Additionally, we found that AdipoR1 and AdipoR2 expression is lower in epithelial ovarian cancer cells than in granulosa tumor
cells. Endogenous 17β-estradiol as well as exogenous estrogens, such as bisphenol A and its chlorinated and brominated analogs
do not affect adiponectin receptor expression. We found that adiponectin inhibited the growth of OVCAR-3 and SKOV-3 cells,
and that this effect was independent of apoptosis. Moreover, adiponectin reverses the stimulatory effects of 17β-estradiol and
insulin-like growth factor 1 on cell proliferation by downregulating the expression of their receptors, whereas progesterone
increased the sensitivity of cancer cells to adiponectin by upregulating AdipoR1 and AdipoR2 expression. These results suggest
interactions between adiponectin and various ovarian steroid hormone and growth factor pathways in ovarian cancer cells.
Introduction
Ovarian cancer remains the leading cause of death among
women, with an estimated 150,000 annual deaths worldwide
[1]. Due to its non-specific symptoms, most cases of ovarian
cancer are detected when the disease has advanced to a late
stage that associates with poor survival. Thus, approaches that
would increase its early detection are urgently needed to re-
duce mortality. Ovarian cancer can be classified into three
types based on the cell of its origin, namely, epithelial, stro-
mal, and germ, with each type conferring different histopath-
ological features and clinical outcomes [2]. Epithelial ovarian
cancer is the most common ovarian malignancy; it originates
in epithelial cells found on the surface of the ovary and ac-
counts for ~ 80–90% of ovarian malignancies. Stromal tu-
mors, on the other hand, account for ~ 7% of ovarian malig-
nancies, and the most frequently diagnosed stromal tumor
type is the granulosa cell tumor (GCT).
There is emerging evidence to indicate that obesity is
the main independent risk factor for ovarian cancer [3–5].
Although the correlation between ovarian cancer and obe-
sity has been linked to hormones, it is not clear how they
can trigger cancer in obese women. Hormones and growth
factors have important roles in regulating cell proliferation,
differentiation, and apoptosis. For example, 17β-estradiol
(E2), progesterone (P4), and insulin-like growth factor 1
(IGF-1) have all been proposed to influence ovarian cancer
development [6, 7]. Adipokines, hormones secreted from
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adipose tissues that may promote obesity, may also affect
cancer development.
Adiponectin, an adipokine with a molecular weight of
30 kDa, is found in the serum, where it exists in four isoforms,
namely, trimeric (90 kDa), hexameric (180 kDa), and high-
molecular-weight (360 and 400 kDa) isoforms [8]. At a serum
concentration of 5–30μg/ml, it is the most abundant circulating
peptide hormone. In obese adults, however, the serum
adiponectin level is reduced [9]. Adiponectin has been reported
to act as an anti-tumor factor by inhibiting cancer cell prolifer-
ation [10, 11]. Other studies report a role for adiponectin in
obesity-associated cancer such as those of the breast, cervix,
and endometrium. However, the role of adiponectin in ovarian
cancer has been studied much less. For example, Jin et al. re-
ported that adiponectin levels were significantly lower in ovar-
ian cancer patients than in healthy individuals, but the reason
for this is not clear [12]. Furthermore, the biological actions of
adiponectin are mediated through interactions with its receptor
subtypes, AdipoR1 and AdipoR2. Li et al. showed that a low
AdipoR1 expression level in cancerous ovarian tissues serves
as an independent prognostic indicator of the disease [13]. In
the human granulosa KGN cell line, AdipoR1 functions in cell
survival, whereas AdipoR2 regulates steroid production [14].
Several endogenous, as well as exogenous factors, includ-
ing insulin, thiazolidinediones, metformin, and bisphenol A
(BPA), can regulate the production and secretion of
adiponectin in the 3T3-L1 adipocyte cell line [15–18]. On
the other hand, several lines of evidence indicate that endo-
crine disrupting chemicals, such as BPA, can induce obesity
[19, 20]. BPA, a commercial product commonly used in poly-
carbonate plastics and epoxy resins [21], possesses estrogenic
activity and promotes ovarian cancer cell proliferation [22, 23]
and migration [24]. Epidemiological studies report that
humans have detectable serum levels of not only BPA, but
also its halogenated derivatives, tetrabromobisphenol A
(TBBPA) and tetrachlorobisphenol A (TCBPA) [25–27].
We aimed to investigate whether adiponectin and its recep-
tors, AdipoR1 and AdipoR2, are expressed in human epithe-
lial ovarian cancer cell lines. We also examined whether BPA
and its analogs can affect the expression of adiponectin and its
receptors in ovarian cancer cells. The effects of adiponectin on
cell proliferation and apoptosis were also examined. Finally,
we investigated whether E2, P4, and IGF-1 can regulate
AdipoR1 and AdipoR2 expression and modulate the effects
of adiponectin on the proliferation of ovarian cancer cells.
Materials and Methods
Cell Culture and Chemicals
OVCAR-3, SKOV-3, and Caov-3 were purchased from the
American Type Culture Collection (Manassas, VA, USA).
COV434 cells were obtained from the European Collection
of Authenticated Cell Cultures (ECACC, Sigma-Aldrich, St.
Louis, MO, USA). The human ovarian serous carcinoma cell
lines OVCAR-3, SKOV-3, and Caov-3 were cultured in
RPMI 1640, McCoy’s, and Dulbecco’s modified Eagle’s me-
dium (DMEM), respectively. Media were supplemented with
10% fetal bovine serum (FBS) (Thermo Fisher Scientific Inc.,
Carlsbad, CA, USA). The human metastatic granulosa cell
line COV434 was cultured in DMEM supplemented with
2 mM L-glutamine (Biowest, Nuaillé, France) and 10% FBS.
All cell cultures were maintained at 37 °C in a humidified
atmosphere containing 5% CO2.
Human adiponectin, 17β-estradiol, progesterone, and
insulin-like growth factor 1 were purchased from Sigma-
Aldrich. BPA (AccuStandard, New Haven, CT, USA) and
E2 were dissolved in absolute ethanol. TBBPA and TCBPA
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA) and dissolved in DMSO. The final concentration of
ethanol and DMSO in the mediumwas 0.1%. Viability of cells
was not affected at this concentration.
Real-Time PCR Analysis
COV434, OVCAR-3, SKOV-3, and Caov-3 cells were seeded
in 96-well plates and cultured until 70% confluent in the indi-
cated media for 24 h. The culture medium was then removed,
and the cells were rinsed with PBS and stored at − 20 °C. To
investigate the effects of E2, P4, IGF-1, BPA, TBBPA, and
TCBPA on the expression of AdipoR1 and AdipoR2, the cul-
ture medium was replaced with fresh medium 24 h before the
cells were treated with compounds. The cells were then ex-
posed to vehicle (medium, 0.1%DMSO, or 0.1% ethanol), E2
(10 nM), P4 (100 μM), IGF-1 (100 ng/ml), or BPA, TBBPA,
or TCBPA (1, 10, and 100 nM) for 24 h. To investigate the
effects of adiponectin on the expression of ERα, ERβ, PR,
and IGF1R, the culture medium was replaced with fresh me-
dium 24 h before the cells were treated with adiponectin at
25 μg/ml for 24 h.
Total RNA was isolated from control and treated cells,
followed by cDNA synthesis using the TaqMan Gene
Expression Cells-to-CT Kit (Applied Biosystems, Foster
City, CA, USA), according to the manufacturer’s instructions.
The lysis solution contained DNase I to digest contaminating
genomic DNA. The resulting cDNA was analyzed by real-
time PCR using a StepOnePlus Real-Time PCR System
(Applied Biosystems) and TaqMan Gene Expression Assays
together with a TaqMan Gene Expression Master Mix and
ROX Reference Dye (Applied Biosystems). The thermal cy-
cling conditions were as follows: 50 °C for 2 min and 95 °C
for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C
for 60 s. Duplicate control cDNA-free samples were prepared
for each gene. The TaqMan Gene Expression Assays used for
real-time PCR were as follows: adiponectin [ADIPOQ, assay
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nos. Hs00605917_m1 and Hs00977214_m1], AdipoR1
[ADIPOR1 , assay no. Hs01114951_m1], AdipoR2
[ADIPOR2, assay no. Hs00226105_m1], ERα [ESR1, assay
no . Hs00174860_m1] , ERβ [ESR2 , a s s ay no .
Hs001100353_m1], PR [PGR, assay no. Hs01556702_m1],
and IGF1R [IGF1R, assay no. Hs00609566_m1]. Expression
levels were normalized to that of GADPH (assay no.
4310884E), and the relative expression was quantified using
the 2−ΔΔCt method [28].
Western Blot Analysis
COV434, OVCAR-3, and SKOV-3 cells were seeded in 24-
well plates and cultured until 70% confluent in the indicated
media for 24 h. The cells were then removed from plates,
transferred to ice-cold lysis buffer, and stored at − 20 °C.
The protein concentrations of the lysates were determined by
the Bradford method (Bio-Rad Protein Assay, Bio-Rad
Laboratories, Hercules, CA, USA). An equal amount of pro-
tein (60 μg) from each sample was assayed. Proteins were
separated by 10% SDS-PAGE, and then transferred to
polyvinylidene fluoride (PVDF) microporous membranes
(Millipore, Billerica, MA, USA) using the Bio-Rad Mini-
Protean 3 System. The membranes were blocked for 1 h in
0.02 M Tris-buffered saline containing 5% bovine serum al-
bumin and 0.1% Tween 20, and then incubated overnight at
4 °C with antibodies specific for human AdipoR1 (cat. no. sc-
46749, Santa Cruz Biotechnology), human AdipoR2 (cat. no.
sc-46751, Santa Cruz Biotechnology), ERα (cat. no. sc-542,
Santa Cruz Biotechnology), PR (cat. no. sc-539, Santa Cruz
Biotechnology), IGF1R (cat. no. ab39675, Abcam,
Cambridge, UK), and PARP (cat. no. #9542, Cell Signaling
Technology). The membranes were then washed three times
in Tris-buffered saline containing 0.1% Tween 20 (TBST) and
incubated for 1 h at room temperature with a species-
compatible horseradish peroxidase-conjugated secondary an-
tibody (cat. no. sc-2020, Santa Cruz Biotechnology). β-Actin
(cat. no. A5316, Sigma-Aldrich) was used as the loading con-
trol. Immunopositive bands were visualized using
WesternBright Quantum HRP Substrate (cat. no. K-12043
D20, Advansta Inc., Menlo Park, CA, USA). Quantification
of protein bands was performed by densitometry using
VisionWorks LS Acquisition and Analysis software (UVP,
LLC Upland, CA).
Cell Proliferation
Cell proliferation was measured using AlamarBlue Cell
Viability Reagent (Invitrogen, Paisley, UK), according to the
manufacturer’s instructions. OVCAR-3 and SKOV-3 cells
were exposed to adiponectin (0.025, 0.25, 2.5, or 25 μg/ml)
for 48 h. In co-treatment experiments, OVCAR-3 cells were
treated with adiponectin (25 μg/ml) and E2 (10 nM), P4
(100 μM), or IGF-1 (100 ng/ml) for an additional 48 h. The
AlamarBlue stock solution was aseptically added to the wells
after 48 h of culture in an amount equaling 10% of the volume
of culturemedium. The reduction of resazurin to resorufin was
determined after 4 h of incubation by measuring the fluores-
cence at an excitation wavelength of 560 nm and an emission
wavelength of 590 nm using an FLx800 fluorescence micro-
plate reader (BioTek Instruments, Winooski, VT, USA). Data
were analyzed using KC JUNIOR Software (BioTek
Instruments).
Caspase-3 Activity
Twenty-four hours before each experiment, the culture medi-
um was replaced with serum-free medium. Treatments
consisted of vehicle or adiponectin (0.025, 0.25, 2.5, or
25 μg/ml) for 24 h. The medium was then removed, and the
plates were stored at − 70 °C. Cells were lysed in caspase
assay buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 0.1%
CHAPS, 1 mM EDTA, 10% glycerol, and 10 mM DTT). The
protein concentrations of the lysates were determined by the
Bradford method (Bio-Rad Protein Assay). An equal amount
of the cytosolic extract (100 μg of protein) from each sample
was analyzed. The assay was carried out by adding 100 μM
Ac-DEVDAMC (Sigma-Aldrich) and incubating the plates at
37 °C. The amount of fluorescent product was monitored con-
tinuously for 120 min with a spectrofluorometer (FLx800
BioTek Instruments) at an excitation wavelength of 355 nm
and an emission wavelength of 460 nm. Data were analyzed
using KC JUNIOR Software, and normalized to fluorescence
levels in vehicle-treated cells.
Statistical Analysis
Statistical data are presented as means ± SD of three indepen-
dent experiments performed in triplicate. Statistical analysis
was carried out using one-way or two-way ANOVA, followed
by Tukey’s test (GraphPad Software, La Jolla, CA, USA). The
level of significance was set at p < 0.05.
Results
Expression of Adiponectin and Its Receptors
in Epithelial Ovarian Cancer Cell Lines
Before investigating the effects of adiponectin on human ep-
ithelial ovarian cancer cells, we examined the expression of
adiponectin and its receptors in epithelial ovarian cancer cell
lines (OVCAR-3, SKOV-3, and Caov-3) and compared the
mRNA levels with those in the granulosa tumor cell line
(COV434). By real-time PCR analyses, all cancer cell lines
failed to express adiponectin (data not shown). Both
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ADIPOR1 and ADIPOR2 receptors were expressed by all cell
lines. The relative quantity (RQ) of each transcript (ADIPOR1
and ADIPOR2) expressed by the granulosa tumor cell line
(COV434) was arbitrarily set at 1. The basal ADIPOR1
mRNA level was lower in the epithelial ovarian cancer cells
(3.5-, 2-, and 1.3-fold in OVCAR-3, SKOV-3, and Caov-3,
respectively) than in the granulosa tumor cell line (Fig. 1a;
p < 0.05). Similarly, the basal ADIPOR2 transcript level was
lower in OVCAR-3, SKOV-3, and Caov-3 cells (6-, 4.3-, and
2.2-fold in OVCAR-3, SKOV-3, and Caov-3, respectively)
than in COV434 cells (Fig. 1b; p < 0.05). The basal
AdipoR1 and AdipoR2 protein levels were examined by
Western blot analysis in COV434, OVCAR-3, and SKOV-3
cells, and the results mirrored those from real-time PCR anal-
yses (Fig. 1c).
Effects of Environmental Estrogens (BPA and Its
Analogs) on the Expression of Adiponectin Receptors
A previous study reported that BPA regulates adiponectin
production and secretion in 3T3-L1 adipocytes. For this rea-
son, we assessed the effects of BPA, TBBPA, and TCBPA on
the expression of AdipoR1 and AdipoR2 in SKOV-3 and
OVCAR-3 cells by real-time PCR analysis. BPA, TBBPA,
and TCBPA at all tested concentrations (1, 10, and 100 nM)
had no effects on ADIPOR1 and ADIPOR2 expression in
SKOV-3 (Fig. 2a) and OVCAR-3 cells (Fig. 2b).
Effect of Adiponectin on OVCAR-3 and SKOV-3 Cell
Proliferation
We examined the ability of adiponectin to affect OVCAR-3
and SKOV-3 cell proliferation. After 48 h of treatment, we
observed a dose-dependent inhibition in the proliferation of
both OVCAR-3 and SKOV-3 cells. Compared with that of
control cells, there was a statistically significant decrease in
proliferation after exposing OVCAR-3 cells to adiponectin at
concentrations of 2.5 and 25 μg/ml (85 ± 1.5% and 76 ± 3%
relative to the control, respectively) (Fig. 3a; p < 0.01,
p < 0.001). Adiponectin at concentrations of 0.025 and
0.25 μg/ml had no effect on the proliferation of OVCAR-3
cells. Similarly, adiponectin decreased SKOV-3 cell prolifer-
ation dose-dependently (87 ± 1.7%, 79 ± 2.9% and 75 ± 2.5%
at 0.25, 2.5, and 25 μg/ml relative to the control, respectively)
(Fig. 3b; p < 0.05, p < 0.001).
Epithelial ovarian cancer cells differ from granulosa tumor
cells in terms of their morphology and clinical behavior. We
found that ADIPOR1 and ADIPOR2 expression was lowest in
OVCAR-3 cells compared with that in the other cells.
Moreover, our finding suggested that adiponectin inhibit
OVCAR-3 and SKOV-3 cell proliferation in a similar manner.
For this reason, OVCAR-3 cells were chosen as an in vitro
model of serous epithelial ovarian cancer for further analysis.
Effect of Adiponectin on Caspase-3 Activity
and Cleaved PARP Protein Expression in OVCAR-3
Cells
In a parallel experiment that employed a caspase-3 activity
assay, we evaluated the effect of adiponectin on caspase-3
activity and cleaved PARP protein expression in OVCAR-3
cells. Adiponectin at all tested concentrations had no effect on
OVCAR-3 caspase-3 activity as well as cleaved PARP protein
expression (Fig. 4).
Effects of E2, IGF-1, and P4 on Adiponectin Reduces
the Proliferation of Cancer Cells
Previous studies reported E2, P4, and IGF-1 to affect ovarian
cancer development, which prompted us to examine the ef-
fects of adiponectin and E2, P4, or IGF-1 on the proliferation
of cancer cells. Consistent with previous results, we found that
Fig. 1 Basal mRNA and protein expression of adiponectin receptors
(AdipoR1 and AdipoR2) in various cancer cell lines. AdipoR1 mRNA
(a), AdipoR2 mRNA (b), and protein expression (c) in a human ovarian
granulosa tumor cell line (COV434 cells) and epithelial ovarian cancer
cell lines (Caov-3, SKOV-3, and OVCAR-3). RQ, relative quantity. The
mRNA levels of ADIPOR1 and ADIPOR2 in COV434 cells were set at
1.0. Statistically significant differences are indicated with different letters
(a < b < c < d, p < 0.05)
HORM CANC (2018) 9:166–174 169
E2 and IGF-1 stimulated OVCAR-3 cell proliferation (115 ±
3% and 138 ± 5% relative to that of the control, respectively)
(Fig. 5; p < 0.05). However, adiponectin reversed E2- and
IGF-1-induced OVCAR-3 cell proliferation; the combined
treatment of adiponectin and E2 or adiponectin and IGF-1
decreased cell proliferation to the basal adiponectin level after
48 h, (75 ± 7% and 86 ± 9%, respectively, vs 80 ± 5%), (Fig.
5; p < 0.05). Although P4 had no effect on OVCAR-3 cell
proliferation, the combined treatment of adiponectin and P4
decreased cell proliferation to below the basal adiponectin
level (67 ± 5% vs 80 ± 5%), (Fig. 5; p < 0.05).
Effects of E2, P4, and IGF-1 on Adiponectin Receptor
Expression
To investigate the mechanism by which adiponectin reduced
E2- and IGF-1-induced cell proliferation, we measured the
mRNA levels of AdipoR1 and AdipoR2 in OVCAR-3 cells
after E2, IGF-1, and P4 treatment. As shown in Fig. 6, E2 and
IGF-1 had no effect on the basal AdipoR1 and AdipoR2
levels. However, the levels of AdipoR1 and AdipoR2 were
higher in OVCAR-3 cells cultured in the presence of P4 than
in control cells (35 ± 6% for AdipoR1 and 31 ± 8% for
AdipoR2 compared with the respective basal levels) (Fig. 6).
Effects of Adiponectin on ERα, ERβ, PGR, and IGF1R
Receptor Expression
Next, we examined whether adiponectin (25 μg/ml) could
affect the mRNA expression of ESR1, ESR2, IGF1R, and
PGR in OVCAR-3 cells. We observed no difference in
ESR2 expression between adiponectin-treated and control
cells (data not shown). By contrast, the levels of IGF1R,
ESR1, and PGR were significantly lower in adiponectin-
treated cells than in control cells (0.83 ± 0.04, 0.74 ± 0.06,
and 0.43 ± 0.1 vs 1 RQ, respectively). The ERα, PR, and
IGF1R protein levels were examined byWestern blot analysis,
Fig. 2 Effects of BPA, TBBPA, and TCBPA (1, 10, and 100 nM) on
AdipoR1 and AdipoR2 mRNA expression in epithelial ovarian cancer
cell lines (SKOV-3, a) and (OVCAR-3, b). ADIPOR1 and ADIPOR2
mRNA expression after exposing cells to the indicated compounds for
24 h. RQ, relative quantity; C, control. The mRNA levels of ADIPOR1
and ADIPOR2 in vehicle-treated cells were set at 1
Fig. 3 Effect of adiponectin (0.025, 0.25, 2.5, and 25 μg/ml) on the
proliferation of OVCAR-3 (a) and SKOV-3 (b) cells after 48 h of treat-
ment. C control. The proliferation rate in vehicle-treated cells was set at
100%. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control cells
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and the results mirrored those from real-time PCR analyses
(Fig. 7).
Discussion
The expression of AdipoR1 and AdipoR2 has been reported in
a human granulosa tumor KGN cell line [14]. However, the
majority (~ 90%) of malignant ovarian tumors are of epithelial
cell origin, and only ~ 7% are classified as ovarian sex cord
tumors, with the most common type being the granulosa tu-
mor [2]. The expression of adiponectin and its receptors in
epithelial ovarian cancer cells has not yet been reported. In
the present study, we found that adiponectin was not
expressed in the granulosa cell line, as well as epithelial ovar-
ian cancer cell lines. These findings suggest that adiponectin
can act on ovarian cancer cells in vivo only as an endocrine
factor. Additionally, our results indicated that both AdipoR1
and AdipoR2 are expressed in various epithelial ovarian
cancer cell lines, and that their expression in these cell lines
was lower than in the granulosa tumor cell line (COV434).
Our observations are consistent with those of Li et al. [13] and
Tiwari et al. [29], who reported AdipoR1 expression in can-
cerous epithelial ovarian tissues. Moreover, Li et al. [13] illus-
trated that epithelial ovarian cancer patients with AdipoR1-
positive expression survived longer than those with
AdipoR1-negative expression. To our knowledge, there is no
information on AdipoR2 expression in human ovarian cancer
tissues. This study is the first to report a lower expression of
AdipoR1 and AdipoR2 in epithelial ovarian cancer cells com-
pared with granulosa tumor cells. This observation may partly
explain why granulosa tumors are generally considered to
have a better prognosis than epithelial ovarian tumors.
Second, we investigated whether BPA and its analogs
could regulate the expression of AdipoR1 and AdipoR2 in
epithelial ovarian cancer cells. We found that low nanomolar
Fig. 4 Effect of adiponectin
(0.025, 0.25, 2.5, and 25 μg/ml)
on caspase-3 activity (a) and
cleaved PARP protein expression
(b) in OVCAR-3 cells after 24 h
of treatment. C control
Fig. 6 Effects of E2 (10 nM), P4 (100 μM), or IGF-1 (100 ng/ml) on
ADIPOR1 and ADIPOR2 expression in OVCAR-3 cells. ADIPOR1 and
ADIPOR2mRNA expression after exposing cells to compounds for 24 h.
RQ relative quantity, C control. The mRNA levels of ADIPOR1 and
ADIPOR2 were set at 1. **p < 0.01, ***p < 0.001 compared with control
cells
Fig. 5 Effects of adiponectin (25 μg/ml) and E2 (10 nM), P4 (100 μM),
or IGF-1 (100 ng/ml) on the proliferation of OVCAR-3 cells after 48 h of
treatment. C control. Statistically significant differences are indicated
with different letters (a < b < c < d < e < f, p < 0.05)
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concentrations of BPA, as well as TBBPA and TCBPA, had
no effects on the expression of both receptors in epithelial
ovarian cancer cell lines (OVCAR-3 and SKOV-3).
Previously, Hugo et al. [30] observed that BPA at 0.1 and
1 nM inhibited adiponectin secretion from human breast adi-
pose tissue explants and abdominal subcutaneous explants.
On the other hand, Kidani et al. [18] indicted that BPA and
BPA-related chemicals, such as bisphenol F, bisphenol E, and
bisphenol B, decreased adiponectin secretion in 3T3-L1 adi-
pocytes. However, there is no information on the effects of
BPA, TBBPA, or TCBPA on AdipoR1 and AdipoR2 expres-
sion in human ovarian cells.
Because the effects of adiponectin on epithelial ovarian
cancer cells are unknown, we examined whether adiponectin
at concentrations reported in the serum and lower can affect
OVCAR-3 and SKOV-3 cell proliferation. We found that
adiponectin inhibited the growth of both cell lines. Similar
results have been observed in various breast cancer cell lines,
including MCF-7 [10], MDA-MB-231 [11, 31], and T47D
[11]. The anti-proliferative effects of adiponectin in breast
cancer cells are sometimes [31], but not always [11, 32], as-
sociated with apoptosis. Considering this, we analyzed the
effect of the adiponectin on ovarian cancer cell apoptosis.
We observed that adiponectin had no effect on OVCAR-3
apoptosis. These data indicated that adiponectin decreased
epithelial ovarian cancer cell proliferation, and that this effect
was independent of apoptosis.
Next, we investigated whether ovarian hormones and a
growth factor (E2, P4, and IGF-1) could affect adiponectin
activity in epithelial ovarian cancer cells. We demonstrated
the antagonistic effect of adiponectin on E2- and IGF-1-
induced epithelial ovarian cancer cell proliferation.
Consistent with previous data, we observed mitogenic activity
after treatment of epithelial ovarian cancer cells with E2 [22,
33] and IGF-1 [34]. In the present study, proliferation was
reduced to the basal adiponectin level in cells exposed to
adiponectin and E2 or adiponectin and IGF-1. These results
are consistent with those of Dieudonne et al. [10], who report-
ed that adiponectin suppressed the proliferation of E2-treated
breast cancer MCF-7 cells. However, there is no information
on the effects of adiponectin on IGF-1-induced proliferation in
ovarian cancer cells.
To gain insight into the mechanism underlying the antago-
nistic effects of adiponectin on E2- and IGF1-induced cell
proliferation, we examinedAdipoR1 and AdipoR2 expression
after E2 and IGF-1 treatment and ERα, ERβ, and IGF1R
expression after adiponectin treatment. Similar to exogenous
estrogens, such as BPA, and endogenous estrogens, we found
that E2 had no effect on AdipoR1 and AdipoR2 expression.
We also found that IGF-1 did not affect AdipoR1 and
AdipoR2 expression. However, adiponectin reduced the ex-
pression of ERα and IGF1R, but not that of ERβ, in epithelial
ovarian cancer cells. In contrast to ERα, ERβ activates anti-
proliferative pathways in ovarian cancer cells [35]. There is
also an inverse correlation between ERβ expression and ovar-
ian tumor progression [36, 37]. Results from this study dem-
onstrated that adiponectin changes the ERα/β ratio by de-
creasing ERα expression in epithelial ovarian cancer cells.
Similar to our observations, Jarde et al. [38] noted that
adiponectin downregulated ERα gene expression in the
MCF-7 breast cancer cell line. However, anti-proliferative
adiponectin effects have been reported for ER-positive [10]
and ER-negative [31] breast cancer cell lines, suggesting that
Fig. 7 Effects of adiponectin (25 μg/ml) on the estrogen receptor (ESR1,
a), progesterone receptor (PGR, b), and insulin-like growth factor type 1
receptor (IGF1R, c) mRNA at 24 h and protein at 48 h expression in
OVCAR-3 cells. RQ relative quantity, C control. The control value was
arbitrarily set at 1. *p < 0.05, **p < 0.01, ***p < 0.001 compared with
control cells
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the effects of adiponectin are not due to interactions with the
estrogen pathway. Indeed, our results indicated that
adiponectin not only interacts with the estrogen pathway, but
also with the IGF-1 pathway.
We also found that P4 had no effect on the proliferation of
OVCAR-3 cells. Murdoch et al. [39] arrived at a similar con-
clusion after performing experiments on P4-treated OVCAR-
3 and SKOV-3 cells. Interestingly, we observed that co-
treatment with adiponectin and P4 potentiated the effects of
adiponectin by reducing cell proliferation to below the basal
adiponectin level. We also found that P4 upregulated
AdipoR1 and AdipoR2 expression, whereas adiponectin
downregulated PGR expression. Thus, the potentiation of
the effects of adiponectin by P4 enabled us to investigate the
responsiveness of different cancer cell lines to the hormone.
On the other hand, the decreased PGR expression altered the
insensitivity of various epithelial ovarian cancer cells to the
anti-proliferative properties of P4 [40]. Our results may be
partly explained by interactions between P4 and leptin path-
ways. It is well documented that leptin, an adipocyte-secreted
hormone, has opposite effects on the proliferation of cancer
cells [41]. For example, Jardé et al. [38] demonstrated that
leptin upregulated PR mRNA expression in MCF-7 cells.
Moreover, P4 inhibited leptin receptor gene expression in
the human endometrium [42]. Our results, together with those
of previous studies, support the contention that the effects of
adiponectin on cancer cells are opposite to those of leptin.
Taken together, these findings indicate that adiponectin re-
presses the proliferation of epithelial ovarian cancer cells and
reverses the stimulatory effects of E2 and IGF-1 on cell pro-
liferation by downregulating the expression of their receptors.
In addition, P4 increased the sensitivity of cancer cells to
adiponectin by upregulating the expression of it receptors.
These results also suggest interactions between adiponectin
and various ovarian steroid hormone and growth factor path-
ways in ovarian cancer cells.
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